In the fast-evolving world of diagnostics and biotechnologies, time-to-market is everything. For companies of all sizes—whether resource-rich or resource-limited—contract assay developers offer a path to faster timelines, reduced risk, and expert guidance. (more…)

As demand for more precise healthcare diagnostics grows, the landscape is shifting. Today, in certain contexts, there’s a strong push for LFAs to move beyond simple “yes or no” answers and deliver accurate, quantitative results that can support critical clinical decisions. (more…)

The current U.S.-China trade war has reignited global concerns over the stability and security of supply chains — especially for critical sectors like diagnostics. For companies developing lateral flow assays and point-of-need tests, even small interruptions in material sourcing can result in delayed launches, failed partnerships, and lost revenue. (more…)

The global lateral flow assay (LFA) market is projected to reach $16.8 billion by 2029, driven by the need for point-of-care testing and early disease detection. The demand for fast, accurate, and accessible diagnostic testing has never been higher. (more…)